<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04003220</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2018/47</org_study_id>
    <nct_id>NCT04003220</nct_id>
  </id_info>
  <brief_title>Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker</brief_title>
  <acronym>ICTUS</acronym>
  <official_title>Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a translational research study with mechanistical objectives and including biological
      samples of patients with thrombocytopenia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective study to collect blood, bone marrow and hair bulb from patients
      with thrombocytopenia, to better understand the mechanism of idiopathic chronic
      thrombocytopenia of undetermined significance (ICTUS)
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of clonality in patients with ICTUS</measure>
    <time_frame>Day 1</time_frame>
    <description>identification of mutations in genes known to be involved in clonal expansion</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Thrombocytopenia</condition>
  <condition>Purpura, Thrombocytopenic</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>MyeloDysplastic Syndrome</arm_group_label>
    <description>platelets &lt;150 G/l and diagnosis of myelodysplasia according to the WHO classification (abnormal bone marrow features).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idiopathic Chronic Thrombocytopenia of Unknown Significance</arm_group_label>
    <description>Acquired thrombocytopenia lasting&gt;6 months, without feature of dysimmunity (antiplatelet Ab, or anti nuclear Ab, anti ENA Ab, ANCA, anti-CCP Ab, cryoglobulinemia), normal bone marrow examination, absence of other thrombocytopenia in the family. All ICTUS patients included in the study will thus have a bone marrow aspiration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immune Thrombocytopenic Purpura</arm_group_label>
    <description>Diagnosis of Immune Thrombocytopenic Purpura (ITP) is made according to the international ITP consensus (diagnostic criteria of Rodeghiero){Provan, 2010 #18}, knowing that a presumptive diagnosis of ITP is made when the history, physical examination, complete blood count, and examination of the peripheral blood smears do not suggest other etiologies for the thrombocytopenia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy volunteers undergoing cardiac surgery</arm_group_label>
    <description>patients with normal blood counts undergoing cardiovascular surgery for valve replacement, or healthy bone-marrow donors</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>The extra samples will be taken Blood sampling</description>
    <arm_group_label>Idiopathic Chronic Thrombocytopenia of Unknown Significance</arm_group_label>
    <arm_group_label>Immune Thrombocytopenic Purpura</arm_group_label>
    <arm_group_label>MyeloDysplastic Syndrome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone marrow sample</intervention_name>
    <description>This bone marrow sampling will be performed for 10 patients with ICTUS, and 10 controls</description>
    <arm_group_label>Idiopathic Chronic Thrombocytopenia of Unknown Significance</arm_group_label>
    <arm_group_label>healthy volunteers undergoing cardiac surgery</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      the samples for research will be taken in the department where the patient is:

        -  Blood sampling: 5 ACD-A tubes (Acid Citrate Dextrose) and 2 EDTA tubes (for 30 ICTUS
           patients, 20 ITP patients, and 20 patients with MDS)

        -  One supplementary tube of bone marrow (for 10 patients with ICTUS, and 10 Healthy
           controls)

        -  25 Hair bulbs (for 20 ICTUS patients)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        In this project we will study 30 patients with ICTUS, 20 ITP with immunological features,
        20 MDS patients and 10 Healthy volunteers (normal bone marrow donors, obtained during a
        sternotomy performed in the cardiac surgery unit).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-80

          -  Nosological criteria for thrombocytopenic patients:

          -  ICTUS: acquired thrombocytopenia lasting&gt;6 months, without feature of dysimmunity
             (antiplatelet Ab, or anti nuclear Ab, anti ENA Ab, ANCA, anti-CCP Ab,
             cryoglobulinemia), normal bone marrow examination, absence of other thrombocytopenia
             in the family. All ICTUS patients included in the study will thus have a bone marrow
             aspiration.

          -  ITP: Diagnosis of ITP is made according to the international ITP consensus (diagnostic
             criteria of Rodeghiero){Provan, 2010 #18}, knowing that a presumptive diagnosis of ITP
             is made when the history, physical examination, complete blood count, and examination
             of the peripheral blood smears do not suggest other etiologies for the
             thrombocytopenia. There is no &quot;gold standard&quot; test that can reliably establish the
             diagnosis. We are concerned that this group of patients may include ICTUS patients.

          -  ITP with immunological features: ITP with detectable anti-platelet antibodies (Ab)
             and/or autoimmunity (anti nuclear Ab, anti ENA Ab, ANCA, anti-CCP Ab,
             cryoglobulinemia), and/or previously responsive to immunomodulatory ITP-directed
             therapies (steroids, intravenous Immunoglobulin, rituximab, splenectomy). We will use
             these patients as non-ICTUS, ITP positive controls.

          -  Thrombocytopenic myelodysplasia: platelets &lt;150 G/l and diagnosis of myelodysplasia
             according to the WHO classification (abnormal bone marrow features).

          -  Healthy controls: patients with normal blood counts undergoing cardiovascular surgery
             for valve replacement, or healthy bone-marrow donors.

          -  Affiliated person or beneficiary of a social security scheme. Free, informed and
             written consent signed by the participant and the investigator (at the latest on the
             day of inclusion and before any examination required by the research).

        Exclusion Criteria:

          -  Age under 18 or over 80

          -  Persons placed under judicial protection,

          -  Persons participating in another research including a period of exclusion still in
             course

          -  Persons in emergency situation,

          -  Pregnant or nursing women,

          -  Women of childbearing age who do not benefit from effective contraception (HAS
             criteria),

          -  Brain death or deceased persons,

          -  Person who doesn't speak French, doesn't read it, doesn't write it, and doesn't have a
             schooling in France.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JAMES, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chloé JAMES, MD,PhD</last_name>
    <phone>+335 57 65 64 78</phone>
    <email>chloe.james@chu-bordeaux.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Immunopathologie Clinique - Hôpital Saint Louis - AP HP</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lionel GALICIER, MD</last_name>
      <phone>+331.42.49.96.90</phone>
      <email>lionel.galicier@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Lionel GALICIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chirurgie cardiaque - Hôpital Haut Lévêque - CHU de Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mathieu PERNOT, MD</last_name>
      <phone>+335.57.65.69.69</phone>
      <email>mathieu.pernot@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Mathieu PERNOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des maladies du sang - Hôpital Haut-Lévêque - avenue de Magellan</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Noel MILPIED</last_name>
      <email>noel.milpied@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Krimo BOUABDALLAH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Sarah DILHUYDY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noel MILPIED</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>service de médecine interne et maladies infectieuses - Groupe hospitalier Sud</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-François VIALLARD, Prof</last_name>
      <email>jean-francois.viallard@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-François VIALLARD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 26, 2019</study_first_submitted>
  <study_first_submitted_qc>June 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2019</study_first_posted>
  <last_update_submitted>June 28, 2019</last_update_submitted>
  <last_update_submitted_qc>June 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

